(VALE) informed that the results of the investigation requested to Cleary Gottlieb Steen & Hamilton LLP on the rupture of the Fundo Dam in Mariana will be disclosed on August 29th at 2:00 pm EDT and it will be broadcasted live via webcast in English and Portuguese. The link will be available on Vale’s webpage. Following the dam rupture, Samarco, along with Vale and BHP Billiton (BHP), Samarco’s shareholders, hired Cleary Gottlieb Steen & Hamilton LLP to carry an external investigation into the cause of the dam rupture. Statoil (STO) announced it isincreasing the value of Johan Sverdrup.The first phase is currently estimated at NOK99 billion, (Capex numbers in nominal terms based on project currency) a reduction of NOK24 billion since the PDO was submitted. The present break-even is reduced to below $25 per barrel for phase 1. 2:55 am Regeneron Pharma and Sanofi ( SNY ) present Phase 3 data for Praluent meets primary endpoint ( REGN ) : Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline (compared to 2% increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75% compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy. find out this hereApheresis is a procedure similar to kidney dialysis where bad ( LDL ) cholesterol is removed from the blood, and is usually reserved for high-risk patients with very high cholesterol unable to achieve their cholesterol-lowering goals on any other therapy. medical laboratory interview questionsDespite being treated with apheresis and entering ODYSSEY ESCAPE with very high LDL cholesterol levels (4.7 millimoles/liter [mmol/L] or 181 milligrams/deciliter [mg/dL]), nearly two-thirds (63%) of patients treated with Praluent no longer required apheresis therapy after six weeks of receiving Praluent.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/inplay-briefing-com-115750752.html